Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS assay selection: sensitivity and accuracy in clinical application.

Molecular biology reports - 1 Mar 2012

Herreros-Villanueva Marta, Aggarwal Gaurav

Abstract excerpt

KRAS mutation status is routinely tested before the administration of chemotherapeutic agents that target EGFR such as cetuximab and panitumumab. Various commercial assays to analyze KRAS mutational status are currently certified for in vitro diagnostic use. However, the differences in the operational characteristics of the different assays have not been investigated. Since different assays could be different in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Techniques

Share to Panitumumab

Share to Patient Selection

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 21656377
DOI: 10.1007/s11033-011-0997-6

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS assay selection: sensitivity and accuracy in clinical application.PMID 21656377Read ↗

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.Semantic proximity Read ↗

KRAS mutations: analytical considerations.Semantic proximity Read ↗

KRAS testing and its importance in colorectal cancer.Semantic proximity Read ↗

A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical SettingSemantic proximity Read ↗

KRAS mutation testing in clinical practice.Semantic proximity Read ↗

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerSemantic proximity Read ↗

Molecular epidemiology and diagnostics of KRAS mutations in human cancer.Semantic proximity Read ↗

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Semantic proximity Read ↗

KRAS mutation testing in metastatic colorectal cancer.Semantic proximity Read ↗

Clinical significance of the KRAS mutation.Semantic proximity Read ↗

KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material.Semantic proximity Read ↗

Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.